454 completed, 31 terminated, 24 unknown, 22 recruiting. 332 Phase 1, 76 Phase 3, 57 Phase 4, 56 Phase 2, 34 Not applicable.
Follow Moxifloxacin: new trials by email Literature Review of Moxifloxacin trials Research Report on Moxifloxacin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Moxifloxacin, Placebo - Endophthalmitis | Phase 2 / Phase 3 | Not yet recruiting | Jason Ahee, M.D. | 60000 | 2027-06-01 | 2026-09-15 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin) - Brucellosis, Osteoarticular Brucellosis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 150 | 2026-11-01 | 2026-10-21 |
| Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 200 | 2026-11-01 | 2026-10-21 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes Clindamycin, Moxifloxacin (400 mg) - Odontogenic Infection, Maxillofacial Infection | Not applicable | Not yet recruiting | Nishtar Medical University | 60 | 2026-10-01 | 2026-10-16 |
| Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery Levofloxacin, Moxifloxacin - Cataract, Postoperative Endophthalmitis | Not applicable | Not yet recruiting | Assiut University | 93 | 2026-09-26 | 2026-09-30 |
| Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE) Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis, Osteoarthritis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 350 | 2026-09-01 | 2026-08-21 |
| A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart Verducatib, Moxifloxacin, Placebo resembling Verducatib - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 56 | 2026-08-20 | 2026-09-09 |
| A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants EPX-100, EPX-100-Matching Placebo, Moxifloxacin - Healthy Participants | Phase 1 | Recruiting | Epygenix | 88 | 2026-08-05 | 2026-10-16 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| Enhanced Treatment Strategy for Disseminated MAC Infection in HIV Patients: A Randomized Controlled Trial Standard Triple Therapy, Experimental: Standard Triple Therapy Plus Fluoroquinolone - Opportunistic Infections, HIV Related, Disseminated Mycobacterium Avium Complex Infection | Not applicable | Not yet recruiting | Shanghai Public Health Clinical Center | 124 | 2026-04-30 | 2026-05-13 |
| A Study in Healthy People to Test How Vicadrostat Affects the Heart Vicadrostat, Placebo matching Vicadrostat, Moxifloxacin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 45 | 2026-04-22 | 2026-09-01 |
| A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects HDM1002 200 mg, HDM1002 400 mg, Placebo - Healthy Adult Subject | Phase 1 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 72 | 2026-03-07 | 2026-05-19 |
| A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants BMS-986278, Placebo, Moxifloxacin - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2026-02-19 | 2026-08-03 |
| A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) Ulonivirine, Moxifloxacin, Ulonivirine Placebo - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 62 | 2026-01-22 | 2026-04-21 |
| A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants. Balinatunfib, Moxifloxacin, Placebo - Cardiac Repolarization, Healthy Volunteers | Phase 1 | Completed | Sanofi | 48 | 2025-12-04 | 2026-06-23 |
| Effects of Energy Drinks on Cardiovascular Endpoints Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule - Healthy Volunteers, Safety After Oral Intake | Phase 4 | Recruiting | University of the Pacific | 3 | 2025-11-01 | 2025-11-26 |
| PRO-232 in Patients Subjected to Cataract Surgery Moxifloxacin / Dexamethasone Ophthalmic Solution, Placebo, Moxifloxacin Hydrochloride, Ophthalmic - Cataract Extraction | Phase 3 | Recruiting | Laboratorios Sophia S.A de C.V. | 134 | 2025-10-27 | 2025-12-26 |
| Effect of Maridebart Cafraglutide on the Heart's Electrical Activity Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide - Overweight, Obesity | Phase 1 | Completed | Amgen | 81 | 2025-10-22 | 2026-09-22 |
Showing 20 of 563. Sign in to see all of them.
Tuberculosis (33) · Tuberculosis, Pulmonary (30) · Pneumonia (14) · Tuberculosis, Multidrug-Resistant (13) · Cataract (12) · Community-Acquired Pneumonia (12) · Pulmonary Disease, Chronic Obstructive (12) · Infections (11) · Bacterial Infections (10) · Bronchitis, Chronic (7) · Lung Diseases (7) · Conjunctivitis, Bacterial (6) · Endophthalmitis (6) · Abscess (5) · Acquired Immunodeficiency Syndrome (5)
Bayer (34) · Pfizer (20) · Boehringer Ingelheim (17) · GlaxoSmithKline (17) · AstraZeneca (16) · Janssen Research & Development, LLC (13) · Eli Lilly and Company (10) · Bristol-Myers Squibb (9) · Alcon Research (8) · Global Alliance for TB Drug Development (7) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Centers for Disease Control and Prevention (6) · Amgen (5) · Hoffmann-La Roche (5) · Johns Hopkins University (5)
United States (259) · Germany (51) · South Africa (42) · China (39) · United Kingdom (35) · Belgium (25) · France (24) · Brazil (22) · South Korea (21) · Canada (18) · Netherlands (18) · Spain (16) · Uganda (15) · Hungary (14) · Philippines (14)
Carlos Sanabria, MD (3) · Ronald Goldwater, MD (3) · Susan Dorman, MD (3)
PMID 33542052, PMID 20716255, PMID 29356761, PMID 33197289, PMID 33964925, PMID 36546625, PMID 36808186, PMID 37980911, PMID 38768617, PMID 10625102, PMID 10870281, PMID 11883966, PMID 12190139, PMID 12781508, PMID 12787214, PMID 14699540, PMID 15088029, PMID 15276398, PMID 15510357, PMID 15840453, PMID 15953905, PMID 16470119, PMID 16518713, PMID 16553634, PMID 16648771, PMID 16675781, PMID 16776446, PMID 16876044, PMID 16940094, PMID 16988514, PMID 17052624, PMID 17116511, PMID 17229548, PMID 17236918, PMID 17408924, PMID 17484797, PMID 17517835, PMID 17666691, PMID 17719384, PMID 17879915, PMID 17884515, PMID 17916243, PMID 18070980, PMID 18088870, PMID 18167394, PMID 18238963, PMID 18366444, PMID 18390528, PMID 18419482, PMID 18663500
2018 (7), 2015 (5), 2017 (4), 2019 (4), 2023 (4), 2009 (3), 2014 (3), 2005 (2), 2008 (2), 2016 (2), 2025 (1), P30CA069533 (1), U01AI068636 (1), U10EY015114 (1)